{{Infobox drug
| drug_name = 
| IUPAC_name = (2''R'',3''S'',5''R'')-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)oxan-3-amine
| image = Omarigliptin.svg
| width = 
| alt = 
| image2 = 
| width2 = 
| alt2 = 
| imageL =
| widthL =
| altL = 
| imageR = 
| widthR = 
| altR = 
| caption =
<!-- Clinical data -->
| pronounce =
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| licence_EU = <!-- EMA requires brand name -->
| licence_US = <!-- FDA may use generic name -->
| DailyMedID = <!-- preference to licence_US -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =      
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_US_comment = 
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status = 在日本上市，但已经停止研发<ref name=stop/>
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = 口服
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites =
| onset = 
| elimination_half-life = 
| duration_of_action =
| excretion =
<!-- Identifiers -->
| CAS_number = 1226781-44-7
| CAS_supplemental  = 
| ATCvet = 
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental  = 
| PubChem = 46209133
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank = 
| ChemSpiderID = 28424182
| UNII = CVP59Q4JE1
| KEGG = D10317
| ChEBI = 
| ChEMBL = 2105762
| NIAID_ChemDB =
| synonyms = MK-3102
<!-- Chemical data -->
| chemical_formula =
| C=17 | H=20 | F=2 | N=4 | O=3 | S=1
| molecular_weight = 398.427506 g/mol
| SMILES = CS(=O)(=O)n1cc2c(n1)CN(C2)[C@@H]3C[C@@H]([C@H](OC3)c4cc(ccc4F)F)N
| StdInChI = 1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
| StdInChI_comment = 
| StdInChIKey = MKMPWKUAHLTIBJ-ISTRZQFTSA-N
| density = 
| melting_point = 
| melting_high = 
| melting_notes = 
| boiling_point = 
| boiling_notes = 
| solubility = 
| specific_rotation = 
| sec_combustion = 
}}

奥格列汀，即'''Omarigliptin''' ('''MK-3102''') ，是一种强效且长效的口服用[[抗糖尿病药|抗糖尿病药]]，是一类[[二肽基肽酶-4抑制剂|DPP-4抑制剂]]。该药物致力于使得[[2型糖尿病|2型糖尿病]]患者能够将用药频率降低到一周一次。该药物由[[默克藥廠|默克藥廠]]开发。<ref name="merck_pdf">{{cite web | url=https://celerion.com/wordpress/wp-content/uploads/2014/04/Celerion_ASCPT-2014_Pharmacokinetics-of-Omarigliptin-Mk-3102-in-Patients-With-Renal-Impairment.pdf | title=Pharmacokinetics of Omarigliptin (Mk-3102), A Once-Weekly Dipeptidyl Peptidase-IV (DPP-4) Inhibitor, in Patients With Renal Impairment | publisher=Merck & Co., Inc. | accessdate=20 September 2015}}</ref>该药物通过抑制DPP-4来提升{{tsl|en|incretin|肠降血糖素|}}水平([[胰高血糖素样肽-1|GLP-1]]和{{tsl|en|gastric inhibitory polypeptide|抑胃肽|GIP}})，<ref name="pmid15780435">{{cite journal |pages=159–65 |doi=10.1016/j.regpep.2004.06.001 |title=Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? |year=2005 |last1=McIntosh |first1=C |last2=Demuth |first2=H |last3=Pospisilik |first3=J |last4=Pederson |first4=R |journal=Regulatory Peptides |volume=128 |issue=2 |pmid=15780435}}</ref><ref name="pmid12697069">{{cite journal |pmc=154101 |doi=10.1186/1472-6823-3-3 |year=2003 |last1=Behme |first1=Margaret T |last2=Dupré |first2=John |last3=McDonald |first3=Thomas J |journal=BMC Endocrine Disorders |volume=3 |page=3 |pmid=12697069 |title=Glucagon-like peptide 1 improved glycemic control in type 1 diabetes |issue=1}}</ref><ref name="pmid7789625">{{cite journal |pages=626–30 |doi=10.2337/diabetes.44.6.626 |title=Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM |year=1995 |last1=Dupre |first1=J. |last2=Behme |first2=M. T. |last3=Hramiak |first3=I. M. |last4=McFarlane |first4=P. |last5=Williamson |first5=M. P. |last6=Zabel |first6=P. |last7=McDonald |first7=T. J. |journal=Diabetes |volume=44 |issue=6 |pmid=7789625}}</ref>从而抑制[[胰高血糖素|胰高血糖素]]释放，使得[[胰岛素|胰岛素]]分泌增加，减缓胃排空，降低[[血糖|血糖]]水平。
==历史==
日本[[医药品医疗机器总合机构|医药品医疗机器总合机构]]在2015年9月28日批准了25毫克与12.5毫克的药片上市，日本也是该药物的首个批准国家。<ref>{{cite web|url=http://www.nasdaq.com/article/merck-marizevonceweekly-dpp4-inhibitor-for-type2-diabetes-approved-in-japan-20150928-00333|title=Merck MARIZEV Once-Weekly DPP-4 Inhibitor For Type2 Diabetes  Approved In Japan|date=28 September 2015|publisher = NASDAQ|accessdate=29 September 2015}}</ref> 但是默克制药宣布该药品不会寻求美国与欧洲的上市。<ref>http://www.mercknewsroom.com/news/company-statements/merck-provides-update-filing-plans-omarigliptin-investigational-dpp-4-inhibi</ref>该药物目前已经停止研发，推测可能是因为安全性不及预期，易发并发症，且药物在价格上也不占优势。<ref name=stop>{{Cite web|url=https://www.yypharm.com/?p=6678|title=默沙东终止长效DPP4抑制剂omarigliptin研发  美中药源|accessdate=2018-03-16|author=|date=|publisher=|language=zh-hans}}</ref>
==参见==
* [[DPP-4抑制剂|DPP-4抑制剂]]
* [[阿格列汀|阿格列汀]]
* [[利格列汀|利格列汀]]
* [[沙格列汀|沙格列汀]]
* [[西格列汀|西格列汀]]
* [[维格列汀|维格列汀]]
==参考资料==
{{reflist}}
{{Oral hypoglycemics}}
[[Category:氟代芳烴|Category:氟代芳烴]]
[[Category:磺胺|Category:磺胺]]